Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Armando Santoro^{1

2}, Garrido Pilar³, Daniel S W Tan⁴, Jon Zugazagoitia⁵, Frances A Shepherd⁶, Alessandra Bearz⁷, Fabrice Barlesi^{8

9

10}, Tae Min Kim¹¹, Tobias R Overbeck¹², Enriqueta Felip¹³, Can Cai¹⁴, Simantini Eddy¹⁴, Tracey McCulloch¹⁵, Eric S Schaefer¹⁶

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy. armando.santoro@cancercenter.humanitas.it.
² Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy. armando.santoro@cancercenter.humanitas.it.
³ Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
⁴ Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
⁵ Department of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain.
⁶ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁷ Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy.
⁸ Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France.
⁹ Faculté de Médecine, Université Paris Saclay, Kremlin Bicêtre, France.
¹⁰ Medical Oncology Department, Gustave Roussy, Villejuif, France.
¹¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
¹² Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
¹³ Department of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
¹⁴ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
¹⁵ Novartis Pharma AG, Basel, Switzerland.
¹⁶ Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA.

PMID: 39574037
PMCID: PMC11580551
DOI: 10.1186/s12885-024-13210-9

Published Erratum

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Armando Santoro et al. BMC Cancer. 2024.

. 2024 Nov 21;24(1):1436.

doi: 10.1186/s12885-024-13210-9.

Authors

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy. armando.santoro@cancercenter.humanitas.it.
² Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy. armando.santoro@cancercenter.humanitas.it.
³ Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
⁴ Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
⁵ Department of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain.
⁶ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
⁷ Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy.
⁸ Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France.
⁹ Faculté de Médecine, Université Paris Saclay, Kremlin Bicêtre, France.
¹⁰ Medical Oncology Department, Gustave Roussy, Villejuif, France.
¹¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
¹² Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
¹³ Department of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
¹⁴ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
¹⁵ Novartis Pharma AG, Basel, Switzerland.
¹⁶ Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA.

PMID: 39574037
PMCID: PMC11580551
DOI: 10.1186/s12885-024-13210-9

No abstract available

PubMed Disclaimer

Erratum for

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC.
Santoro A, Pilar G, Tan DSW, Zugazagoitia J, Shepherd FA, Bearz A, Barlesi F, Kim TM, Overbeck TR, Felip E, Cai C, Eddy S, McCulloch T, Schaefer ES. Santoro A, et al. BMC Cancer. 2024 Oct 24;24(1):1307. doi: 10.1186/s12885-024-12841-2. BMC Cancer. 2024. PMID: 39448966 Free PMC article. Clinical Trial.

References

1. Santoro A, Pilar G, Tan DS, et al. Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. BMC Cancer. 2024;24:1307. 10.1186/s12885-024-12841-2. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- BioMed Central
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Affiliations

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Authors

Affiliations

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials